Mosaiques therapeutics has developed a range of biomarker tests for a number of chronic diseases. Among these are tests for diabetes, coronary artery disease (CAD) and chronic kidney disease (CKD)[2,3]. These tests are based on a range of peptides that are excreted in urine and form a "biomarker fingerprint" or signature for the health of an individual. These biomarkers were developed for clinical diagnostic purposes and to inform clinicians on treatment progression. They have high specificity and sensitivity for each disease. The clinical biomarker patterns have been validated in a number of blinded studies [4,5]. They can detect the onset of a disease before any symptoms develop.
The tests can also be used to show a significant effect on these chronic diseases after a dietary change. The burden of chronic diseases is rapidly increasing worldwide. Eating a healthy diet is seen a way to prevent or delay the onset of these diseases. But to claim a product is healthy there must be proof. Mosaiques therapeutics has piloted the use of clinical biomarkers in dietary intervention studies. The initial investigation was on a polyphenol rich (P-R) drink verses placebo. The data indicated that the P-R drink may have benefits for cardiovascular health. The second study was set up to examine the effect of the phenolics in olive oil on heart health and provided proof that the intake of 20 ml of olive oil per day can have a statistically significant effect on the biomarker of CAD independent of phenolic content .
This type of data forms the basis for a strong health claim application with considerably less efforts than the conventional approach, including a smaller number of volunteers.
Mosaiques therapeutics utilizes revolutionary CE-MS technology (capillary electrophoresis coupled to mass spectrometry). We are highly experienced in the efficient and time-saving assessment of newly developed as well as already existing pharmaceutical substances. Our approach in clinical proteomics enables the accurate clinical characterisation of patients and controls (high fidelity phenotyping). CE-MS profiling will accelerate drug development by ascertainment of statistically significant data from a small number of patients (defined cohorts) plus an enhancement in the determination of pharmaceutical drug safety.
Disease state specific polypeptide patterns obtained by our CE-MS technology help to select an appropriate therapy. Therapeutic effects of administered drug can be displayed and controlled in the polypeptide patterns. This enables optimization of applied therapy (e.g. dosage modification).
 Delles et al., 2010. Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J. Hypertens. 28, 2316-2322.
 Argiles et al., 2013. CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS One 8, e62837.
 Zurbig et al., 2012. Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy. Diabetes 61, 3304-3313.
 Mischak and Schanstra, 2011. CE-MS in biomarker discovery, validation, and clinical application. Proteomics. Clin. Appl. 5, 9-23.
 Stalmach et al., 2013. Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications. Electrophoresis 34, 1452-1464.
 Mullen et al., 2011. A pilot study on the effect of short-term consumption of a polyphenol rich drink on biomarkers of coronary artery disease defined by urinary proteomics. J Agric Food Chem;59(24):12850-7.
 Silva et al., 2015. Impact of a 6-wk olive oil supplementation in healthy adults on urinary proteomic biomarkers of coronary artery disease, chronic kidney disease, and diabetes (types 1 and 2): a randomized, parallel, controlled, double-blind study. The American Journal of Clinical Nutrition.